ライフサイエンスコーパス: neovasculature

1 es targeted to molecular signatures on tumor neovasculature.

2 he RESDECs participated in forming the tumor neovasculature.

3 s in prostate cancer and in tumor-associated neovasculature.

4 cated in the successful development of tumor neovasculature.

5 human prostate tissues, and the surrounding neovasculature.

6 eceptors expressed selectively in angiogenic neovasculature.

7 t PSMA is also expressed in tumor-associated neovasculature.

8 owing endothelium and limit establishment of neovasculature.

9 expression, enhancing apoptosis, or reducing neovasculature.

10 g circulation time and leakage through tumor neovasculature.

11 ors and is required for development of tumor neovasculature.

12 ents and oxygen supplied by tumor-associated neovasculature.

13 yze sequential gene expression in developing neovasculature.

14 umor cells and indirect effects on the tumor neovasculature.

15 on is associated with the development of the neovasculature.

16 s for immunotherapy as well as inhibit tumor neovasculature.

17 ere mainly on the smooth muscle cells of the neovasculature.

18 e a loss of angiotensin II receptor on tumor neovasculature.

19 n can be contributors to all lineages of the neovasculature.

20 are supported in their growth by a dedicated neovasculature.

21 are highly expressed on tumors and the tumor neovasculature.

22 ules with antivascular activity selective to neovasculature.

23 during angiogenesis on the tumor associated neovasculature.

24 tiation between tip cells and stalk cells of neovasculature.

25 on the surface of tumor cells and the tumor neovasculature.

26 e the morphology and function of postinfarct neovasculature.

27 dicine," for which the ideal target is tumor neovasculature.

28 n experimental in vivo representation of the neovasculature.

29 I protein was localized selectively to tumor neovasculature.

30 mors previously shown to express PSMA on the neovasculature.

31 enabling detailed small-animal PET of tumor neovasculature.

32 itates the homing of progenitor cells to the neovasculature.

33 , which are expressed on actively remodeling neovasculature.

34 COX-2 expression is restricted to the tumor neovasculature.

35 igh doses can augment the development of the neovasculature.

36 and endothelial cells in areas of developing neovasculature after focal cerebral ischemia in adult ra

37 identified in corpus luteal and endometrial neovasculature after inductive ovulation.

38 toxin, has been shown to target pathological neovasculature and activate complement (C3), thereby ind

39 endothelial precursor cells incorporate into neovasculature and have been successfully used as vehicl

40 Importantly, RNAi-MMP-9 reduces tumor neovasculature and increases tumor cell death.

41 int suppression of angiogenesis in the tumor neovasculature and induction of tumor cell apoptosis.

42 llin nanoparticles were used to suppress the neovasculature and inhibit Vx-2 adenocarcinoma developme

43 te cancer cells and nonprostatic solid tumor neovasculature and is a target for anticancer imaging an

44 xpression on many solid tumors and the tumor neovasculature and its role in metastasis and angiogenes

45 oliferation, diffuse invasion, and prominent neovasculature and necrosis.

46 othelium cadherin that is expressed in tumor neovasculature and on endothelial progenitor cells in th

47 tegrins present in both the tumor-associated neovasculature and on the surface of ovarian cancer cell

48 ressed on endothelial cells lining the tumor neovasculature and on tumor cells; the active site of fa

49 vitro and in vivo as well as their homing to neovasculature and outgrowth into differentiated cell ty

50 for prospectively studying the link between neovasculature and plaque vulnerability.

51 nation of GSC-derived pericytes disrupts the neovasculature and potently inhibits tumor growth.

52 ust neoplastic cells but also stromal cells, neovasculature, and a gamut of immune cells.

53 MAbs directed toward tumor cells, tumor neovasculature, and host negative immunoregulatory eleme

54 enograft tumors expressing human Thy1 on the neovasculature, and on the neovasculature of a genetic m

55 ue formation, including the establishment of neovasculature, and the formation of fibrotic scar tissu

56 cellular elements such as stromal cells, the neovasculature, and the full gamut of immune cells.

57 tides that recognize CD13 receptors in tumor neovasculature are of high interest, in particular due t

58 , and cancers (tumor cells, as well as tumor neovasculature) are key targets.

59 COX-2 is expressed within human tumor neovasculature as well as in neoplastic cells present in

60 of donor endothelial cells into the newborn neovasculature as well as tissue vascularity were signif

61 cinar epithelium and the prostate and in the neovasculature associated with tumors, prostate-specific

62 d from inflammatory cells at 3 days and from neovasculature at 7 days after operation.

63 newborn mice, and osteoblasts and associated neovasculature at sites of endochondrial ossification in

64 anoparticles penetrated into the leaky tumor neovasculature but did not appreciably migrate into the

65 enovirus could prevent or regress tumor-free neovasculature, but it was progressively less effective

66 s identified as a specific biomarker of PDAC neovasculature by proteomic analysis.

67 re are two distinct processes by which tumor neovasculature can be built: angiogenesis is the formati

68 y, and pericyte recruitment into the growing neovasculature can be rescued by local intramuscular del

69 of the formation of a pathological choroidal neovasculature (CNV) that damages the macular region of

70 ake of TRC105 (which binds to CD105 on tumor neovasculature) conjugated HMSN in the 4T1 murine breast

71 ncreased histopathology, suggesting that the neovasculature contributes to tissue damage during colit

72 pha(v)beta(3) integrin receptor expressed on neovasculature, could increase systemic RIT efficacy of

73 Histologic analysis revealed specific tumor neovasculature damage after treatment with 4 doses of VE

74 However, the level of neovasculature did not translate into significant improv

75 f tumors such as physicochemical properties, neovasculature, elasticity, surface electrical charge, a

76 tolytic immune response against the targeted neovasculature endothelial cells and tumor cells.

77 SMA has been reported exclusively within the neovasculature endothelial cells of nonprostatic cancers

78 II immunoconjugate bound to tissue factor on neovasculature endothelial cells.

79 Neovasculature enhancement was dependent on the relaxivi

80 ene glycol (PEG), as a means to target tumor neovasculature expressing integrins and used to deliver

81 promoted the establishment of well-organized neovasculature formation.

82 ival, reduces infarct expansion, and induces neovasculature formation.

83 lly, we assessed the extent and character of neovasculatures formed by freshly isolated and cultured

84 y, the presence of PSMA on nonprostate tumor neovasculature has opened the possibility of PSMA-target

85 Capillary endothelial cells of neovasculature in 137 malignant tumors (non-brain) obtai

86 cells, inhibits cell invasion, and decreases neovasculature in HUVEC and also tumor volume in EAT mou

87 can be effectively used to image mouse tumor neovasculature in lesions as small as several millimeter

88 We searched for new markers of neovasculature in PDAC and assessed their potential for

89 ility of 2ME2 to target both tumor cells and neovasculature in preclinical models led to ongoing eval

90 h had been shown to destroy the pathological neovasculature in solid tumors, on the formation of lase

91 bbits in comparison with sparse incidence of neovasculature in the control animals.

92 we undertook studies to examine whether the neovasculature in tumors also differed depending upon tu

93 s technique can be used to directly identify neovasculature in vivo and to facilitate gene therapy by

94 to tumor vessels and independently assembled neovasculature in vivo.

95 marrow-derived cells incorporating into the neovasculature, indicating that recruitment and/or reten

96 ization of solid tumors and their supporting neovasculature is a fundamental prerequisite for effecti

97 The tumor neovasculature is also characterized by an abnormal vasc

98 cancer is a highly vascular tumor, where the neovasculature is unique in that it arises only from the

99 f plaque composition, including macrophages, neovasculature, necrotic core, calcification, loose matr

100 genic therapy, the factors controlling tumor neovasculature need to be systemically maintained at sta

101 human Thy1 on the neovasculature, and on the neovasculature of a genetic mouse model of PDAC.

102 ive anti-PSMA mAbs reacted strongly with the neovasculature of a wide spectrum of malignant neoplasms

103 PSMA was consistently expressed in the neovasculature of a wide variety of malignant neoplasms

104 ntigen is also expressed in tumor-associated neovasculature of a wide variety of malignant neoplasms.

105 It is concluded that even in the neovasculature of brain tumors, Pgp has the facility to

106 lignant prostate epithelial cells and by the neovasculature of many tumor types; however, it is not e

107 However, P-gp expression in the neovasculature of metastatic brain tumors is similar to

108 mmunohistochemical expression of P-gp in the neovasculature of metastatic tumors, as well as our rece

109 n the surface of prostate carcinomas and the neovasculature of most other solid tumors.

110 dent growth, cell invasion, and formation of neovasculature of NSCLC.

111 K1 reduced the proliferation Ki-67 index and neovasculature of orthotopic xenografts.

112 expressed in prostate cancer and within the neovasculature of other solid tumors.

113 we could demonstrate PSMA expression in the neovasculature of several PSMA PET-positive lung cancers

114 ent murine bone marrow incorporated into the neovasculature of subsequently transplanted syngeneic ne

115 irectly related to VEGFR-2 expression in the neovasculature of the angiogenic rim.

116 y permits direct, real-time visualization of neovasculature of the atherosclerotic plaque and associa

117 ons stained with X-gal demonstrated that the neovasculature of the developing tumor frequently compri

118 ved endothelial cells were found only in the neovasculature of the newborn recipients.

119 ors is similar to the P-gp expression in the neovasculature of the primary, extracranial tumor.

120 quely or highly expressed in tumor cells and neovasculature of tumors of various origins.

121 n expressed in prostate cancer cells and the neovasculature of various solid tumors.

122 gly activated (>300-fold) in response to the neovasculature or to the low extracellular pH in tumours

123 , these preliminary studies suggest that the neovasculature originates by sprouting from larger, host

124 resented to predict the development of tumor neovasculature over time and the specific, vascular accu

125 )beta(3)-GNBs homed specifically to immature neovasculature (PECAM(+), Tie-2(-)) along the immediate

126 ation was to determine whether the amount of neovasculature present in advanced carotid plaques can b

127 There was extensive destruction of the tumor neovasculature, presumably mediated by the factor VII im

128 PSMA expression in neovasculature provides a possible explanation for this

129 eraction between tumors and their associated neovasculature provides an explanation for the focal eff

130 elated with macrophage (r = 0.54, P = .004), neovasculature (r = 0.68, P < .001), and loose matrix (r

131 elated with macrophage (r = 0.75, P < .001), neovasculature (r = 0.71, P < .001), and loose matrix (r

132 ow and shear rates increase within the tumor neovasculature, reaching values comparable with those me

133 n the intracranial cTVT, suggesting that its neovasculature represented an interruption of the normal

134 dings indicate that generation of functional neovasculature requires close titration of NO-Tie2 signa

135 In addition, the neovasculature resulting from ZFP-induced expression of

136 xtent to which Pgp expression in brain tumor neovasculature retains its capacity to limit drug penetr

137 and quantitatively with the amount of leaky neovasculature seen on T1Gd.

138 gliomas have higher P-gp expression in their neovasculature, similar to the greater intrinsic express

139 ntegrin alphavbeta3 is expressed only on the neovasculature, such as in the HNSCC tumors.

140 ation with phosphorylated TF specifically on neovasculature, suggesting that phosphorylation of the T

141 led significantly higher VAP-1 expression in neovasculature than in the preexisting vessels.

142 useful for characterizing tumors with sparse neovasculature that are unlikely to have a reduced growt

143 like 4 can restrict tumor growth and disrupt neovasculature, the effect of inhibiting Notch receptor

144 nscription factor that promotes formation of neovasculature through activation of target genes, such

145 t for attacking tumor cells as well as tumor neovasculature to facilitate immunotherapeutic treatment

146 )beta(3))-fumagillin nanoparticles decreased neovasculature to negligible levels relative to control;

147 revealed as functionally important for tumor neovasculature, using kinase inhibitors targeting their

148 on of the anti-PSMA mAbs to tumor-associated neovasculature was confirmed by CD34 immunohistochemistr

149 The neovasculature was temporally responsive to VEGFR2 immun

150 Three stages in the development of the tumor neovasculature were characterized by intravital microsco

151 1 and FaDu) that induce alphavbeta3-positive neovasculature when transplanted into nude mice.

152 nd procoagulant activity on tumor-associated neovasculature when used in isolation perfusion, the lat

153 we hypothesize that E4G10 can only bind the neovasculature, where VE-cadherin has not yet engaged in

154 TMV and demonstrate that stimulation of the neovasculature with cytokines and chemoattractants can r

155 The formation of neovasculature with functionally defective blood vessels

156 Superfusion of the lymphotoxin-stimulated neovasculature with leukotriene B4 (LTB4) resulted in st

157 ously and provided specific detection of the neovasculature within 2 hours by routine magnetic resona

158 Neovasculature within atherosclerotic plaques is believe

159 MRI provides an indication of the extent of neovasculature within carotid atherosclerotic plaque.

160 -1 is up-regulated in the small, angiogenic, neovasculature within the fibrotic septa of cirrhotic li

161 oscopically evident perfusion of the corneal neovasculature without affecting macroscopic measurement